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Abstract
Autophagy is the major intracellular system which is critical for the removal of 
harmful protein aggregates and malfunctioning organelles. Dysfunctional autoph-
agy is associated with a multitude of human diseases, such as protein aggregation 
in Alzheimer’s disease and non-successful aging. Major interest exists in the dietary 
manipulation of the autophagy pathway activity, so as to tune the cell’s protein 
degradation capabilities and to prevent cell death onset. It has recently become clear 
that the machinery required to degrade protein cargo has a distinct activity level 
which can be altered through specific dietary modulation. Moreover, this activity 
may differ from that of the proteinaceous cargo. Overall, brain health and success-
ful aging are characterized by limited protein aggregation, with a distinct molecular 
signature of maintained autophagy function. However, it is largely unclear how to 
control autophagy through dietary interventions with a precision that would allow 
to maintain minimal levels of toxic proteins, preserving neuronal cell viability and 
proteostasis. In this chapter, we carefully dissect the relationship between autoph-
agy-modulating drugs, including caloric restriction mimetics and their impact on 
neuronal autophagy, in the context of preserving brain health.
Keywords: autophagic flux, caloric restriction, proteotoxicity, Alzheimer’s disease, 
neurodegeneration, autophagosome, lysosome
1. Introduction
At the beginning of the twentieth century, life expectancy at birth was about 
45 years. Today, this figure has markedly increased to nearly 77 years [1]. Recent 
estimates [1] predict that in the next four decades, the world’s proportion of people 
aged 65 years and older will account for nearly 22% of the total population—from the 
present 800 million to 2 billion people. Although this increase in life expectancy is 
reflective of the healthcare achievements [2], the socioeconomic costs associated with 
a higher chronic disease burden have necessitated the development of robust preven-
tion and management strategies that are both safe and immediately executable.
2. The role of protein aggregation in Alzheimer’s disease
Alzheimer’s disease (AD) is a debilitating neurodegenerative disease, affecting 40 
million people worldwide [3]. The prevalence of AD is strongly correlated with age, 
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imposing a greater socioeconomic burden as life expectancy continues to increase. 
Clinically, AD is associated with the progressive loss of essential cognitive functions 
and progressive hippocampal and cortical brain atrophy [4]. Current AD treatment 
Food and Drug Administration (FDA)-approved drugs include N-methyl-D-aspartic 
acid (NMDA) receptor antagonist memantine and cholinesterase inhibitors done-
pezil, galantamine, and rivastigmine [5]. These drugs augment cholinergic neuro-
transmission or attenuate excitotoxic neuronal injury. However, they only provide 
palliative benefits at best, with limited impact on the underlying disease mechanisms. 
Therefore, there is an urgent need for interventions that not only impact the aging 
process in favor of sustained brain health but also promote successful brain aging 
in the context of neurodegenerative diseases. AD is pathologically defined by the 
widespread brain distribution of amyloid-beta peptide (Aβ) plaques, neurofibrillary 
tangle (NFT) formation, as well as synaptic and neuronal loss [6]. Despite growing 
understanding of the disease, it remains unclear how these pathological features 
relate to the specific disease processes. The amyloid cascade hypothesis continues to 
serve as the predominant model of AD pathology. This hypothesis suggests the over-
production of Aβ, particularly an increase in Aβ [42] relative to Aβ [40], as the causal 
trigger in the disease process [7]. Aβ is derived from the amyloidogenic cleavage of 
the amyloid precursor protein (APP), protein cleaved by two endoproteases: the beta-
site APP-cleaving enzyme 1 (BACE1/β-secretase) and γ-secretase enzyme. Briefly, 
APP is cleaved by BACE1, releasing sAPPβ and leaving the membrane-bound C99 
carboxy-terminal fragment that is subsequently processed by γ-secretase to generate 
Aβ, a nontoxic P3 peptide, and the APP intracellular domain (AICD) [7]. γ-Secretase 
cleavage results in a C-terminal heterogeneity of the resulting Aβ peptide population. 
Hence, Aβ peptides of different lengths exist, with Aβ40 being the most abundant 
(~80–90%), followed by the more hydrophobic and fibrillogenic Aβ42 (~5–10%) 
form which is the principal peptide aggregated in the AD brain [8].
Similar to AD, protein aggregation is also a hallmark of neuronal cell death onset 
in Parkinson’s disease (PD). PD is pathologically defined by the formation of intra-
neuronal inclusions consisting of aggregated α-synuclein (α-syn) and the presence 
of Lewy neurites and Lewy bodies (LBs) [9]. This neuropathology is associated with 
impaired functioning of intracellular protein degradation mechanisms [10]. Thus, 
strategies to either degrade or prevent the initial accumulation of Aβ oligomers and 
α-syn may be promising in the treatment or prevention of AD and PD, respectively.
3. Protein quality surveillance machinery
The postmitotic nature of neuronal cells makes them highly susceptible to the 
accumulation of protein aggregates. Hence, the maintenance of protein homeo-
stasis is critical to maintain neuronal function, particularly with age. Although the 
etiology and molecular mechanisms underlying the pathological changes in AD 
are not fully understood, studies suggest that localized deficits in the autophagy 
pathway are likely to precede the formation of Aβ plaques or NFTs [11]. Autophagy 
is a highly conserved catabolic process that is critical for the systemic removal of 
long-lived proteins, protein aggregates, and dysfunctional organelles and serves as 
a major regulator of longevity in various species [12]. This process is triggered by 
various stressors, e.g., low nutrient levels, and proteotoxicity [13]. Proteotoxicity is 
by the of functional conformation as mature proteins misfold due to normal aging, 
posttranslational modifications, or inherent mutations [14]. In the absence of intra-
cellular corrective mechanisms, this proteotoxicity can lead to uncontrolled protein 
aggregation, impair the cells’ ability to maintain protein homeostasis, and promote 
cell death onset [14]. Depending on the cargo sequestered, and the mechanism 
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through which cargo is delivered to the lysosome, autophagy encompasses at least 
three subtypes: microautophagy, chaperone-mediated autophagy (CMA), and 
macroautophagy (Figure 1).
In microautophagy, lysosomal membrane invaginations mediate the internaliza-
tion of cytosolic cargo into small vesicles that detach into the lumen for degradation 
[15]. CMA refers to a selective form of autophagy, whereby cytosolic proteins 
containing a CMA targeting motif—an amino-acid sequence biochemically similar 
to KFERQ—are bound by heat shock-cognate chaperone of 70 kDa (HSC70). 
HSC70 targets these proteins to the lysosomal membrane, where after binding to 
the cytosolic tail of lysosome-associated membrane protein type-2A (LAMP2A), 
proteins are unfolded and translocated across the lysosomal membrane aided by the 
lysosome-resident form of HSC70 (lys-hsc70) for degradation by the luminal prote-
ases [16]. Of the three pathways, macroautophagy (hereafter referred to as autoph-
agy) is the most extensively characterized and most relevant to AD. Therefore, this 
review will focus on the role of macroautophagy as the key mechanism which may 
be exploited to promote brain health and successful brain aging.
4. The tight orchestration of autophagy
Autophagy serves as the cell’s principal quality control system which medi-
ates the degradation of entire cytoplasmic materials through a series of stages 
characterized by the de novo formation of double-membraned vesicles, termed 
autophagosomes, which sequester cytoplasmic cargo and fuse with lysosomes to 
form autolysosomes. This process culminates in cargo degradation and subsequent 
recycling of the resulting macromolecules. To date, more than 30 highly conserved 
Figure 1. 
Schematic model of the three main types of autophagy described in mammalian cells.
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autophagy-related (ATG) genes have been implicated in the core autophagy 
machinery [17]. The autophagic process is tightly regulated, with distinct sets 
of Atg proteins forming diverse complexes which control different stages of this 
pathway under basal and stressful conditions.
The induction of autophagy is primarily mediated by two complexes. Firstly, 
the initiation complex, which triggers the formation of a phagophore structure 
(or isolation membrane), comprises the Unc-51-like kinase-1 (ULK1), Atg13, 
Atg101 and the focal adhesion kinase family-interacting protein of 200 kDa 
(FIP200) [17]. Secondly, the nucleation complex drives the phosphorylation of 
phosphatidylinositol (PI) to produce phosphatidylinositol 3-phosphate (PI3P), a 
membrane-bound lipid which requires the class III phosphatidylinositol 3-kinase 
(C3PI3K) vacuolar protein sorting 34 (Vps34) to recruit Beclin1, Vps15, Atg14L, 
or Ambra1 in the region of phagophore formation, termed the omegasome 
[17]. Autophagosome formation is mediated by two ubiquitin-like conjugation 
reactions. The first reaction results in the formation of the Atg12-Atg5-Atg16L1 
conjugation complex which facilitates the expansion of the phagophore mem-
brane. In the second reaction, Atg12-Atg5 associates with Atg16L1 and localizes 
to the outer membrane of the pre-autophagosomal structures, in turn catalyzing 
the recruitment and conjugation of microtubule-associated protein 1 light chain 
3 (MAP1LC3/Atg8/LC3) with a membrane phospholipid, phosphatidyletha-
nolamine (PE), through the action of Atg4, Atg7, and Atg3 [18]. Atg4 catalyzes 
the conversion of the cytosolic form of LC3 (LC3-I) to the autophagosome 
membrane-associated form (LC3-II), which serves as an indicator of autophago-
some pool size at a given time [18]. Mature autophagosomes ultimately fuse with 
lysosomes to form autolysosomes, in which sequestered cargo is degraded and 
released back into the cytosol for reuse [18]. Autophagic flux, the rate of pro-
tein degradation through the autophagy pathway [19, 20], provides an accurate 
measure of this dynamic process.
5.  Key signaling pathways in the regulation of autophagy during  
nutrient stress
The mammalian target of rapamycin complex 1 (mTORC1) is a component of 
mTOR, the master regulator of cellular metabolism in response to environmental 
cues. mTORC1 integrates various signaling networks to promote protein synthesis 
by suppressing catabolic processes under nutrient-rich conditions [21]. In addition 
to the class I phosphatidylinositol-3-kinase (PI3K) and the Akt signaling pathway, 
the tuberous sclerosis (TSC) tumor suppressor complex (TSC1/TSC2) is an impor-
tant upstream regulator of mTORC1, with loss-of-function mutations in either 
complex leading to the constitutive activation of mTORC1 [22]. Under conditions 
of nutrient excess, growth factors such as insulin-like growth factor 1 (insulin/
IGF1) activate their cognate receptors, subsequently activating the PI3K/Akt path-
way [23]. Activated Akt inhibits TSC1/TSC2, resulting in the activation of mTORC1 
[23]. Subsequently, mTORC1 suppresses autophagy activity by phosphorylating (i) 
components of the ULK1 complex; (ii) Atg14L or Beclin1 regulator (Ambra1); (iii) 
the Beclin1-binding protein, UV radiation resistance-associated gene (UVRAG); or 
(iv) the transcription factor EB (TFEB), a key regulator of lysosomal and autoph-
agy gene expression [24]. Therefore, mTORC1 can inhibit autophagy by targeting 
different components of the core autophagy machinery (Figure 2).
Under conditions of nutrient stress, mTORC1 activity is suppressed, result-
ing in the activation of the ULK1 complex [24]. Cellular energetic sensor, AMP-
activated protein kinase (AMPK), positively regulates autophagy to maintain energy 
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homeostasis under energy depleted conditions. Briefly, AMPK phosphorylates 
TSC2- and mTORC1-binding partner regulatory-associated protein (Raptor) [25], 
thereby suppressing mTORC1 activity. Additionally, AMPK can bind and phos-
phorylate ULK1, freeing this complex to initiate autophagy under both nutrient and 
ATP deplete conditions [26]. Thus, initiation of autophagy can be jointly regu-
lated by mTORC1 and AMPK, to increase the cell’s capacity to adapt to metabolic 
perturbations.
6. Decreased autophagy with age
Consistent with the transcriptional downregulation of autophagy during healthy 
aging in the human brain [27], the impairment of autophagy has been found to 
decrease life span in various model systems [28]. Screening for chronological 
aging factors, Matecic et al. [29] published one of the earliest findings implicating 
impaired autophagy activity in the shortened life span of S. cerevisiae mutants. Most 
compelling findings came from Atg5 [30] or Atg7 [31] knockout mice which revealed 
that impaired autophagic function led to early postnatal death, the accumulation of 
intracellular inclusion bodies, and neurodegeneration. Since insufficient/impaired 
autophagy contributes to aging, it is conceivable that increasing the activity of this 
process could influence aging, in favor of life span extension. Indeed, it is becoming 
increasingly clear that modulation strategies that enhance autophagy activity attenu-
ate proteotoxicity, while defects in this pathway have been implicated in increased 
Figure 2. 
Regulation of autophagy by cellular nutrient status.
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risk for cell death onset with age [28]. Autophagy dysfunction has been extensively 
documented in AD progression, where the accumulation of incompletely degraded 
cytoplasmic within autophagic vacuoles (AVs) has been shown to be a pathological 
hallmark of insufficient autophagic induction in AD [32]. This process is further 
exacerbated by the presence of APP and its processing enzymes within the AVs [33], 
indicating that autophagy may regulate both Aβ generation and clearance. Indeed, 
insufficient expression of autophagy core protein Beclin1 has been shown to increase 
the expression levels of APP, Aβ, and the C-terminal fragment (CTF) in cultured 
neurons, in early AD patients, and mouse models of AD, while Beclin1 overexpres-
sion had the opposite effect [34]. Therefore, the modulation of autophagy may 
ameliorate the loss of proteostasis in AD. Indeed, rapamycin, an mTORC1 inhibitor, 
has been shown to reduce Aβ load and tau pathology and improve cognitive function 
[35], with this reduction being most pronounced when rapamycin was administered 
prior to the widespread deposition of Aβ [36]. Therefore, the identification of novel 
treatment strategies, or repurposing of readily available autophagy-inducing drugs 
to promote successful brain aging, has attracted considerable attention. Additionally, 
drugs/strategies with dual-functional capabilities in both the inhibition of Aβ 
production and upregulation of its clearance may prove especially beneficial in the 
attenuation of Aβ pathology. To this end, the use of calorie restriction (CR) dietary 
interventions and CR mimetics (CRMs) may offer a relatively simple, safe, and 
inexpensive avenue to induce autophagy and offset the decline of autophagy activity 
associated with age. CR, here defined as a reduction in caloric/energetic intake with-
out causing malnutrition, remains not only the most robust and reproducible dietary 
intervention known to increase life span and delay aging but is also a most potent 
physiological inducer of autophagy [37]. In fact, short-term fasting in mice has been 
shown to markedly induce neuronal autophagy, translating in neuroprotection [38].
7. CR effects on aging and neurodegeneration
7.1 CR regimes
Intermittent fasting (IF) is the most studied CR regime in humans. IF involves 
alternating between periods of ad libitum (AL) caloric intake and partial or 
complete CR in which food intake is restricted for prolonged time periods [39]. 
The majority of IF animal studies have involved either alternating IF (AIF) or 
time-restricted intermittent fasting (TRIF), with both resulting in neuroprotec-
tion, as evidenced by the enhancement of neuronal plasticity, increased levels of 
brain-derived neurotrophic factor (BDNF), and increased resistance to metabolic 
stress [40]. Goodrick and colleagues revealed that rats maintained on a lifelong AIF 
regime lived nearly twice as long as rats fed AL [41]. More recently, CR regimes 
have also been shown to attenuate Aβ neuropathology in the brains of AD mouse 
models [42]. In agreement, AD mice maintained for 1 year on either AIF or a 40% 
CR diet beginning from 5 months of age were not found to exhibit the cognitive 
impairments observed in AL fed AD mice [43]. However, the beneficial effects 
of CR on aging and maximal life span in humans remain unclear given the ethi-
cal controversies associated with long-term survival studies in normal-weight 
humans, the lack of validated biomarkers of aging, and the limited compliance to 
prolonged CR regimes [44]. Notably, gender-based differences have been reported 
in response to CR regimes [45]. For example, work by Martin et al. [46] revealed 
that while male and female rats maintained on a CR regime for 6 months had 
similar levels of circulating triglycerides and energy-regulating hormones (insulin, 
leptin, adiponectin, and ghrelin), the changes were quantitatively greater in males. 
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The most compelling support for the beneficial effects of CR on longevity stems 
from epidemiological studies of the older Okinawan population, which is the 
longest lived population to date [47]. The longevity and apparent rarity of progres-
sive neurodegenerative diseases amongst? this population are associated with strict 
adherence to their traditional Okinawan diet, consisting of soybean-based foods, 
unrefined carbohydrates, and moderate protein intake with emphasis on root veg-
etables (sweet potatoes), fish, and lean meats [48]. However, given the paucity of 
long-term CR studies in humans, there is insufficient data to determine the optimal 
CR regimen and the degree of CR needed to achieve sustained brain health.
7.2 CR and brain health
During the aging process, neuronal cells are exposed to increased oxidative and 
metabolic stress associated with numerous cellular modifications [49]. These modifi-
cations are aggravated in neurodegenerative diseases, where neuronal injury is most 
pronounced in the hippocampus and cortex region. Strong evidence from animal 
studies suggests that CR promotes enhanced synaptic plasticity, resulting in increased 
brain resistance to metabolic stressors, and delays brain aging [50]. Studies suggest that 
long-term CR, from 3 to 11 months of age, had a survival-promoting effect on newly 
formed glial cells in the hippocampus region of 2-, 18-, and 24-month-old mice [51]. 
In AD mouse models maintained on a 6–14 week CR regime, a significant reduction in 
Aβ and astrocytic activation was observed [52]. Hence, exploitation of the mechanisms 
through which CR augments brain health may aid in the development of lifestyle-
based therapeutics in the treatment of AD and other neurodegenerative diseases. 
Although the exact mechanisms through which CR promotes health and life span are 
not fully understood, nutrient signaling pathways have been implicated (Figure 3). Of 
considerable importance to the CR-induced effects on brain aging is the induction of 
autophagy following the activation of metabolic energy sensors AMPK and sirtuin-1 
(SIRT1) or the inhibition of the insulin/IGF1 pathway and mTORC1 signaling [53].
7.3 SIRT1
SIRT1 is a nicotine amide NAD+-dependent histone deacetylase, which exhib-
its increased expression following CR in many tissues, including the brain [54]. 
Importantly, SIRT1 overexpression has also been shown to promote autophagy by 
activating essential Atg proteins [55]. SIRT1 can further stimulate autophagy by 
deacetylating and activating the Forkhead box (FOXO) family of transcription factors 
which act as key regulators of longevity under CR conditions [56]. SIRT1 may further 
promote longevity through FOXO-dependent induction of stress response genes [56].
7.4 AMPK
AMPK is activated in response to low energy levels, e.g., under CR conditions 
[57], suggesting that AMPK may play a role in CR-induced longevity. Indeed, 
increased AMPK activity has been found to extend life span in C. elegans and 
Drosophila model systems, while its inhibition shortened life span [58]. The 
mechanism underlying AMPK-induced life span extension under CR is thought 
to involve the direct phosphorylation of peroxisome proliferator-activated recep-
tor G coactivator-1α (PGC-1α), a key regulator of mitochondrial metabolism and 
biogenesis, and FOXO transcription factors, thereby targeting these components for 
SIRT1-mediated activation [59]. Importantly, AMPK stimulates autophagy through 
the direct phosphorylation of ULK1, or the activation of TSC1/TSC2, which in turn 
inhibits mTORC1 [25], thereby allowing autophagy induction.
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7.5 Insulin/IGF1 signaling
Inhibition of insulin/IGF1 signaling following CR or growth factor removal 
has been reported to increase life span, delay the onset of age-related diseases, 
and increase oxidative stress resistance in various species, including humans [60]. 
CR-induced downregulation of the insulin/IGF1 pathway in turn induces the 
activation of SIRT1, resulting in the activation of FOXO transcription factors [61].
7.6 mTORC1 signaling
mTORC1 is activated by growth factors, amino acids, or increased glucose 
levels, and is thought to control life span through various mechanisms, including 
the regulation of autophagy [62]. Indeed, autophagy has been shown to be essen-
tial for life span expansion in mTOR knockout yeast [63] and C. elegans model 
systems in which impaired autophagic function has been shown to abolish the life 
span extension induced by mTOR inhibition under CR conditions [28]. The con-
vergence of CR-induced signaling pathways on autophagy supports the assertion 
that this process is intricately involved in aging. Therefore, the precision control 
of brain autophagy activity could mediate sustained brain health with age.
Figure 3. 
The targeting of nutrient-triggered pathways by selective calorie restriction mimetics in longevity and the 
promotion of brain health. CR, calorie restriction; CRM, caloric restriction mimetic; IF, intermittent fasting; 
SIRT1, sirtuin-1; mTORC1, mammalian target of rapamycin complex 1; AMPK, AMP-dependent protein 
kinase; PGC-1α, peroxisome proliferator-activated receptor gamma coactivator 1-α; insulin/IGF-1, insulin/
insulin-like growth factor-1; PI3K, phosphoinositide 3-kinase; FOXO, Forkhead box O; EP300, E1A-binding 
protein p300.
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8. Antiaging pharmacological CR mimetics
Given the challenge to adhere to prolonged CR regimes, as well as selective side 
effects, such as decreased body temperature [64] and slowed wound healing [65], 
compounds that elicit similar beneficial effects on aging, health, and life span as CR 
could be a more practical alternative. This area of research has sparked considerable 
interest in the use CRM drugs, or CRM supplements as adjuvant therapy to delay 
the aging process, particularly during mid- to late life. Currently, the most widely 
studied CRM candidates are resveratrol, rapamycin, 2-deoxy-D-glucose (2DG), 
metformin, and spermidine (Figure 3).
8.1 Resveratrol
Resveratrol is a polyphenol compound isolated from the skins of red grapes, 
with red wine (5 mg/L on average) being the principal source of this compound 
[66]. Daily consumption of grape and blueberry polyphenols has also gained 
interest as CRMs for the prevention and treatment of neurodegenerative diseases. 
For example, studies indicate that the combined dietary supplementation of grape 
and blueberry polyphenols may have beneficial effects on age-related cognitive 
decline, improving episodic memory impairment in elderly subjects [67] and pre-
venting the onset of learning and cognitive deficits in aged mice [68]. However, 
resveratrol has been found to be the most potent polyphenol compound and is to 
date the most thoroughly studied CRM, first identified and implicated in life span 
extension in a yeast model system [69]. Work by Baur et al. [70] revealed that 
resveratrol significantly increased survival in middle-aged mice on a high-calorie 
diet compared to that of mice on a standard diet by nearly 31%. In addition, resve-
ratrol increased insulin sensitivity, reduced IGF1 levels, activated AMPK/PGC-1α 
signaling, and improved motor function [70]. Similar benefits have been reported 
in response to resveratrol supplementation in nonhuman primate models fed a 
high-fat diet [71, 72]. In the latter study, resveratrol improved adipose insulin 
levels and reduced the inflammatory response caused by the high-fat diet [72], 
while the former study revealed that resveratrol prevented diet-induced arterial 
wall inflammation [71].
Naturally sourced resveratrol is poorly absorbed in humans [73]. Hence, 
high-purity resveratrol-mimetic drugs, such as ResVida™, have been developed to 
ensure its sustained release [74]. In a recent study, 30-day resveratrol supplemen-
tation (150 mg/day ResVida™) in humans led to a decrease in circulating glucose 
levels, inflammatory markers, triglycerides, and systolic blood pressure [74]. In 
contrast, others have reported no significant changes in the above parameters in 
obese men following resveratrol supplementation [75]. Longevinex® is another 
commercially available resveratrol supplement shown to induce SIRT1 and PGC-1α 
and increase mitochondrial biogenesis in the brain [76]. Prolonged Longevinex® 
supplementation has been shown to result in increased levels of LC3-II, Beclin1, 
and FOXO transcription factors. Therefore, it appears conceivable that prolonged 
Longevinex® may influence brain health, in part, by inducing neuronal autoph-
agy. Work by Vingtdeux et al. [77] has also revealed that resveratrol can decrease 
extracellular Aβ accumulation by inducing autophagy through the activation of 
AMPK. Long-term resveratrol treatment is well tolerated in humans [78], with 
significantly reduced Aβ levels and improved memory retention observed in AD 
mouse models [79], making this compound a promising CRM candidate for the 
treatment of AD.
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8.2 Rapamycin
The suppression of mTORC1 activity is associated with a significant improvement 
in both health and life span in various organisms, while increased activity is associated 
with old age in humans [80]. Hence, the use of mTORC1 inhibitor rapamycin may 
have potential applications as a CRM. Currently, rapamycin is clinically used as an 
immunosuppressant to prevent the rejection of kidney transplants in patients [66]. In 
AD mouse models, rapamycin treatment has been shown to improve cognitive ability 
and reduce Aβ and tau pathology, with these observations being linked to increased 
autophagic induction [81]. However, it has been reported that prolonged rapamycin 
treatment in rodents leads to the development of hyperlipidemia, glucose intolerance, 
and high levels of free fatty acids in skeletal muscle [82]. In contrast, lifelong intermit-
tent administration of rapamycin for 2 weeks/month was found to extend life span 
in mice [81], suggesting that intermittent rapamycin administration may be more 
beneficial. In a separate study, adult mice maintained on lifelong rapamycin treat-
ment, starting at 2 months of age, performed significantly better on a task measuring 
spatial learning and memory compared to age-matched mice on the control diet [83]. 
However, rapamycin did not improve cognition in adult mice with pre-existing age-
dependent cognitive deficits [83], suggesting that rapamycin may have better cognitive 
outcomes prior to the onset of cognitive deficits.
Rapamycin is unstable in water; thus, different oral preparations such as 
nanoparticles [84] have been formulated to increase its bioavailability. Rapatar, a 
rapamycin formulation based on Pluronic block copolymers as nanocarriers, has 
been shown to have significantly higher bioavailability after oral administration 
[85]. Rapatar has been shown to increase life span and delay carcinogenesis during 
lifelong treatment administered at intermittently low doses (0.5 mg/kg) in tumor-
prone mice [86]. The advantage of rapamycin is its FDA-approved status for various 
clinical applications in humans; however, the relevance for longevity in humans has 
yet to be established given its immunosuppressive effects.
8.3 Metformin
Metformin is a first-line drug approved for the treatment of diabetes [87], 
which also targets the insulin/IGF1 pathway, mTORC1, AMPK, and SIRT1 [88]. 
Metformin is rapidly distributed to many tissues following partial absorption, 
whereas the luminal concentration in the gastrointestinal tract remains high after 
a single oral dose [89]. Patients with type 2 diabetes have an increased risk of 
developing AD [90], as insulin has been shown to prevent Aβ oligomer formation 
in a dose-dependent matter [90]. A 12-year cohort study revealed that metformin 
supplementation reduced the AD risk in type 2 diabetes patients, with the risk 
being further reduced when metformin was combined with an antihyperglycemic 
agent, sulfonylurea [91]. In contrast, a case-control study revealed that long-term 
metformin-treated type 2 diabetes patients had a slightly higher risk of developing 
AD [92]. Despite these contradictory findings, metformin remains a promising 
CRM, but further research is required to unravel its effects on brain health.
8.4 2DG
2DG is a well-established glycolysis inhibitor first identified by Lane et al. [93] 
as a potential CRM drug. In this study, rats fed with a 2DG supplemented diet at 
varying weight-dependent doses revealed that 2DG was toxic at a high dosage, 
while at the lower dosage, 2DG supplementation had beneficial effects, including 
reduced blood insulin levels [93]. Rodents maintained on a 2DG-supplemented 
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diet for 2 weeks increased neuronal resistance in AD [94] and PD [95] models. 
While 7 weeks of 2DG supplementation at a dosage of 0.04% has been shown to 
attenuate amyloid pathology and increase the levels of BDNF in an AD mouse 
model [96], toxicity studies revealed that 2DG supplementation at a dosage of 
0.2–0.4% may induce cardiotoxicity [97]. 2DG has been linked to the upregula-
tion of CR-related signaling pathways, specifically increased activation of AMPK 
and SIRT1 [93]. Hence, 2DG remains a viable CRM candidate provided the dose-
dependent toxicity can be fully established.
9. Autophagy-inducing agents
Given the cell’s declining capacity to sustain efficient autophagic degradation 
with age, it is not surprising that autophagy dysfunction plays a key role in patho-
logical processes common to aging and neurodegeneration in the elderly [98]. The 
modulation of autophagic activity may thus be a promising strategy to offset the 
progression of neurodegenerative processes with age [99]. In addition to adhering to 
low CR regimes, and the use of CRM drugs, autophagy-induced life extension may 
also be mediated using the histone acetylase inhibitor, spermidine. Unlike other 
autophagy-inducing drugs, spermidine has shown no adverse effects during lifelong 
administration in mice [100], with clinical data indicating good safety and toler-
ability in elderly subjects during long-term dietary supplementation [101].
9.1 Spermidine
Spermidine is a naturally occurring polyamine that has been shown to decline 
throughout the aging process in humans [102]. Accordingly, spermidine dietary 
supplementation in mice (26 weeks) and humans (2 months) has been shown to 
increase blood polyamine concentrations [103, 104]. Studies reveal that spermidine 
influences life span, partly, by inducing autophagy through the suppression of E1A-
binding protein p300 (EP300), an acetyltransferase that transfers acetyl groups 
from acetyl coenzyme A to core Atg proteins, thereby inhibiting this pathway [105]. 
Indeed, He et al. [99] revealed that spermidine’s life-extending effects were abol-
ished when autophagy activity was suppressed through Atg7 or Beclin1 knockdown 
in vivo, consistent with a causal connection between autophagy induction, neuro-
protection, and longevity.
Spermidine’s autophagy-inducing potency has been quantified to be equivalent 
to that of rapamycin [106]. Although dietary supplementation with spermidine 
has emerged as a promising prevention strategy in aging individuals with an 
elevated risk of developing AD, the spermidine concentration required for optimal 
autophagy activity with healthy aging in humans remains unknown. A recent 
study revealed that spermidine supplementation had no toxic effects even at high 
concentrations in mice and in older adults at risk for AD [101]. Improved memory 
performance was reported in the aged subjects after 3 months of spermidine intake 
compared to the placebo group [107], suggesting that nutritional spermidine may 
potentially delay memory loss with age.
10. Screening for autophagy-inducing CRMs
Considerable efforts have been made to identify autophagy-inducing drugs 
which may attenuate the risk for age-associated diseases. Recently, Kaizuka 
et al. [108] developed an autophagic flux probe which was used to rank 
Feed Your Mind - How Does Nutrition Modulate Brain Function throughout Life?
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Figure 4. 
Matching autophagy induction with autophagic flux decline and dysfunction in brain health and pathology associated 
with cognitive impairment.
Rank Drug GFP/RFP (%) Pathology Reference
1 Ciclopirox olamine 17.3 Cancer Zhou et al. [109]
17 Cladribine (2-CDA) 51.1 AD model Hayes et al. [110]
27 Sertraline hydrochloride 58.8 Depression Rainey et al. [111]
29 Loperamide 
hydrochloride
61.7 Huntington’s 
disease model
Williams et al. [112]
47 Azacitidine 70.0 Hematopoiesis 
disorders
Abdulhaq and Rossetti 
[113]
Modified from Kaizuka et al. [108].
Table 1. 
Autophagy inducers identified using a sensitive autophagic flux probe.
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autophagy-inducing drugs according to their level of potency by screening an 
approved drug library. The autophagic flux probe, i.e., GFP-LC3-RFP-LC3∆G, 
is a fusion protein consisting of GFP-LC3 and RFP-LC3, with the C-terminal 
glycine of RFP-LC3 being deleted. An equal amount of GFP-LC3 and RFP-LC3∆G 
is generated in the cytosol, and upon autophagy induction, GFP-LC3 is degraded 
within autolysosomes, while RFP-LC3∆G remains in the cytosol and serves as an 
internal control. GFP-LC3-RFP-LC3∆G-expressing cells were treated with can-
didate drugs at varying concentrations for 24 hrs under both nutrient-rich and 
starvation conditions. The resulting GFP/RFP signal ratio was measured using 
a microplate reader, with a low GFP/RFP ratio indicating a robust autophagy 
inducer (Table 1). Caution is recommended during cell transfection, as homolo-
gous recombination can occur between the two LC3 proteins of the probe. Thus, 
the isolation of properly expressing GFP-LC3-RFP is recommended. Expression 
levels of the probe may also vary among different cells/tissues; thus, cells/tissues 
with similar RFP expression levels should be compared. Lastly, the probe has a 
relatively low time resolution, making it more ideal for the detection of basal 
autophagy [108].
Of the 47 autophagy inducers identified, 3 were of relevance to neuroprotection. 
Importantly, these data indicate firstly, that autophagy activity can be measured 
accurately and hence standardized and, secondly, that neuronal autophagy decline 
in aging or neurodegeneration may be matched with an autophagy inducer that is 
suitable to offset autophagy dysfunction at the respective levels of autophagy activ-
ity (Figure 4). Further studies using these drugs in the context of healthy brain 
aging as well as AD pathology are required.
Other antiaging nutrients identified to date, including antioxidants (vitamins A, 
C, D, and E; quercetin; and coenzyme Q10), and phytochemicals, such as curcumin 
and epigallocatechin-3-gallate, have been shown to enhance autophagy activity [114]. 
However, there is a paucity of studies on their overall health benefits in humans.
11. Healthier dietary patterns for successful aging?
Research on the “nutrition transition” reveal that urban areas of develop-
ing north and sub-Saharan African countries, Asia, Latin America, and the 
Middle East share similar dietary pattern shifts [115]. One commonality of this 
shift is the increased consumption of fat and sugar-laden foods associated with 
increased risk for age-associated and lifestyle-based diseases. The consumption 
of nutritionally dense CRM foods, such as marine-based carotenoid-rich food, 
sweet potatoes, legumes, low-GI grains, fruits, and various flavonoids used in the 
Okinawan diet, is thought to be the most beneficial food choices for successful 
aging [48].
12. Future considerations for successful brain aging
Should we restrict our calories/frequently consume CRMs in order to preserve 
brain health and maintain a sufficiently high neuronal autophagic flux with age? 
Cumulative evidence from over 70 years of CR research provides compelling sup-
port for the role of CR-induced autophagic activity in brain health and longevity 
[116]. Therefore, a CR regime, alone or in combination with the dietary supple-
mentation of a potent autophagy-inducing CRM, could contribute substantially to 
successful brain aging, delaying the onset of detrimental effects associated with 
neuronal proteotoxicity.
Feed Your Mind - How Does Nutrition Modulate Brain Function throughout Life?
14
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Acknowledgements
The authors acknowledge financial support from the South African National 
Research Foundation (NRF), the South African Medical Research Council 
(SAMRC), and the Cancer Association of South Africa (CANSA).
Author details
Claudia Ntsapi, Andre du Toit and Ben Loos*
Department of Physiological Sciences, Faculty of Natural Sciences, University of 
Stellenbosch, Stellenbosch, South Africa
*Address all correspondence to: bloos@sun.ac.za
15
Dietary Impact on Neuronal Autophagy Control and Brain Health
DOI: http://dx.doi.org/10.5772/intechopen.85228
References
[1] Bloom DE, Chatterji S, et al. 
Macroeconomic implications of 
population ageing and selected 
policy responses. The Lancet. 
2015;385(9968):649-657
[2] Lopreite M, Mauro M. The effects 
of population ageing on health 
care expenditure: A Bayesian VAR 
analysis using data from Italy. Health 
Policy (Amsterdam, Netherlands). 
2017;121(6):663-674
[3] Hebert LE, Weuve J, et al. Alzheimer 
disease in the United States (2010-
2050) estimated using the 2010 census. 
Neurology. 2013;80(19):1778-1783
[4] Sabuncu MR, Desikan RS, et al. The 
dynamics of cortical and hippocampal 
atrophy in Alzheimer disease. Archives 
of Neurology. 2011;68(8):1040-1048
[5] Behrens S, Rattinger GB, et al. Use 
of FDA approved medications for 
Alzheimer’s disease in mild dementia is 
associated with reduced informal costs 
of care. International Psychogeriatrics. 
2018;30(10):1499-1507
[6] Blennow K, Hampel H, et al. 
Cerebrospinal fluid and plasma 
biomarkers in Alzheimer disease. Nature 
Reviews. Neurology. 2010;6(3):131-144
[7] Hardy J, Selkoe DJ. The amyloid 
hypothesis of Alzheimer’s disease: 
Progress and problems on the 
road to therapeutics. Science. 
2002;297(5580):353-356
[8] Saito T, Suemoto T, et al. Potent 
amyloidogenicity and pathogenicity 
of Aβ43. Nature Neuroscience. 
2011;14(8):1023-1032
[9] Spillantini MG, Crowther RA, 
et al. Alpha-Synuclein in filamentous 
inclusions of Lewy bodies from 
Parkinson’s disease and dementia 
with lewy bodies. Proceedings of 
the National Academy of Sciences 
of the United States of America. 
1998;95(11):6469-6473
[10] Xilouri M, Brekk OR, et al. 
Alpha-Synuclein and protein 
degradation systems: A reciprocal 
relationship. Molecular Neurobiology. 
2013;47(2):537-551
[11] Correia SC, Resende R, et al. 
Alzheimer’s disease-related misfolded 
proteins and dysfunctional organelles 
on autophagy menu. DNA and Cell 
Biology. 2015;34(4):261-273
[12] Vellai T, Takács-Vellai K, et al. The 
regulation of aging: Does autophagy 
underlie longevity? Trends in Cell 
Biology. 2009;19(10):487-494
[13] Kroemer G, Mariño G, et al. 
Autophagy and the integrated 
stress response. Molecular Cell. 
2010;40(2):280-293
[14] Scrivo A, Bourdenx M, et al. 
Selective autophagy as a potential 
therapeutic target for neurodegenerative 
disorders. Lancet Neurology. 
2018;17(9):802-815
[15] Li W, Li J, Bao J. Microautophagy: 
Lesser-known self-eating. Cellular 
and Molecular Life Sciences. 
2012;69(7):1125-1136
[16] Kaushik S, Cuervo AM. The 
coming of age of chaperone-mediated 
autophagy. Nature Reviews. Molecular 
Cell Biology. 2018;19(6):365-381
[17] Mizushima N, Yoshimori T, 
et al. The role of Atg proteins in 
autophagosome formation. Annual 
Review of Cell and Developmental 
Biology. 2011;27:107-132
[18] Ravikumar B, Moreau K, et al. 
Plasma membrane contributes to the 
formation of pre-autophagosomal 
Feed Your Mind - How Does Nutrition Modulate Brain Function throughout Life?
16
structures. Nature Cell Biology. 
2010;12(8):747-757
[19] Klionsky DJ, Abdelmohsen K, et al. 
Guidelines for the use and interpretation 
of assays for monitoring autophagy (3rd 
edition). Autophagy. 2016;12(1):1-222
[20] Loos B, du Toit A, J-HS H. Defining 
and measuring autophagosome 
flux—Concept and reality. Autophagy. 
2014;10(11):2087-2096
[21] Jhanwar-Uniyal M, Amin AG, 
et al. Discrete signaling mechanisms of 
mTORC1 and mTORC2: Connected yet 
apart in cellular and molecular aspects. 
Advances in Biological Regulation. 
2017;64:39-48
[22] Inoki K, Li Y, et al. TSC2 is 
phosphorylated and inhibited by Akt 
and suppresses mTOR signalling. 
Nature Cell Biology. 2002;4(9):648-657
[23] Ikenoue T, Inoki K, et al. Essential 
function of TORC2 in PKC and Akt turn 
motif phosphorylation, maturation 
and signalling. The EMBO Journal. 
2008;27(14):1919-1931
[24] Medina DL, Settembre C, 
et al. Methods to monitor and 
manipulate TFEB activity during 
autophagy. Methods in Enzymology. 
2017;588:61-78
[25] Inoki K, Zhu T, et al. TSC2 
mediates cellular energy response to 
control cell growth and survival. Cell. 
2003;115(5):577-590
[26] Laker R, Drake J, et al. Ampk 
phosphorylation of Ulk1 is required for 
targeting of mitochondria to lysosomes 
in exercise-induced mitophagy. Nature 
Communications. 2017;8(1):548
[27] Lipinski M, Zheng B, et al. Genome-
wide analysis reveals mechanisms 
modulating autophagy in normal 
brain aging and in Alzheimer’s disease. 
Proceedings of the National Academy 
of Sciences of the United States of 
America. 2010;107(32):14164-14169
[28] Tóth M, Sigmond T, et al. Longevity 
pathways converge on autophagy genes 
to regulate life span in Caenorhabditis 
elegans. Autophagy. 2008;4(3):330-338
[29] Matecic M, Smith D, et al. A 
microarray-based genetic screen for 
yeast chronological aging factors. PLoS 
Genetics. 2010;6(4):e1000921
[30] Hara T, Nakamura K, et al. 
Suppression of basal autophagy in 
neural cells causes neurodegenerative 
disease in mice. Nature. 
2006;441(7095):885-889
[31] Komatsu M, Waguri S, et al. Loss of 
autophagy in the central nervous system 
causes neurodegeneration in mice. 
Nature. 2006;441(7095):880-884
[32] Cataldo A, Hamilton D, et al. 
Properties of the endosomal-lysosomal 
system in the human central nervous 
system: Disturbances mark most 
neurons in populations at risk to 
degenerate in Alzheimer’s disease. 
Journal of Neuroscience: The Official 
Journal of the Society for Neuroscience. 
1996;16(1):186-199
[33] Yu WH, Cuervo AM, et al. 
Macroautophagy--a novel Beta-amyloid 
peptide-generating pathway activated in 
Alzheimer’s disease. The Journal of Cell 
Biology. 2005;171(1):87-98
[34] Pickford F, Masliah E, et al. The 
autophagy-related protein beclin 1 
shows reduced expression in early 
Alzheimer disease and regulates 
amyloid beta accumulation in mice. 
The Journal of Clinical Investigation. 
2008;118(6):2190-2199
[35] Spilman P, Podlutskaya N, et al. 
Inhibition of mTOR by rapamycin 
abolishes cognitive deficits and reduces 
amyloid-beta levels in a mouse model 
of Alzheimer’s disease. PLoS One. 
2010;5(4):e9979
17
Dietary Impact on Neuronal Autophagy Control and Brain Health
DOI: http://dx.doi.org/10.5772/intechopen.85228
[36] Majumder S, Richardson A, et al. 
Inducing autophagy by Rapamycin 
before, but not after, the formation 
of plaques and tangles ameliorates 
cognitive deficits. PLoS One. 
2011;6(9):e25416
[37] Madeo F, Zimmermann A, et al. 
Essential role for autophagy in life 
span extension. The Journal of Clinical 
Investigation. 2015;125(1):85-93
[38] Alirezaei M, Kemball C, et al. 
Short-term fasting induces profound 
neuronal autophagy. Autophagy. 
2010;6(6):702-710
[39] Patterson RE, Laughlin GA, et al. 
Intermittent fasting and human 
metabolic health. Journal of the 
Academy of Nutrition and Dietetics. 
2015;115(8):1203-1212
[40] Mattson MP. Lifelong brain 
health is a lifelong challenge: From 
evolutionary principles to empirical 
evidence. Ageing Research Reviews. 
2015;20:37-45
[41] Goodrick CL, Ingram DK, et al. 
Effects of intermittent feeding upon 
growth, activity, and life span in 
rats allowed voluntary exercise. 
Experimental Aging Research. 
1983;9(3):203-209
[42] Schafer MJ, Alldred MJ, et al. 
Reduction of β-amyloid and γ-secretase 
by calorie restriction in female 
Tg2576 mice. Neurobiology of Aging. 
2015;36(3):1293-1302
[43] Halagappa VKM, Guo Z, et al. 
Intermittent fasting and caloric 
restriction ameliorate age-related 
behavioral deficits in the triple-
transgenic mouse model of Alzheimer’s 
disease. Neurobiology of Disease. 
2007;26(1):212-220
[44] Anastasiou CA, Karfopoulou 
E, et al. Weight regaining: From 
statistics and behaviors to physiology 
and metabolism. Metabolism. 
2015;64(11):1395-1407
[45] Anisimov VN, Popovich IG, et al. 
Sex differences in aging, life span and 
spontaneous tumorigenesis in 129/Sv 
mice neonatally exposed to metformin. 
Cell Cycle (Georgetown, Tex.). 
2015;14(1):46-55
[46] Martin B, Pearson M, et al. 
Sex-dependent metabolic, 
neuroendocrine, and cognitive 
responses to dietary energy 
restriction and excess. Endocrinology. 
2007;148(9):4318-4333
[47] Rosenbaum MW, Willcox BJ, et al. 
Okinawa: A Naturally Calorie Restricted 
Population. Aging and Longevity. 
Netherlands: Springer; 2010. pp. 43-53
[48] Willcox BJ, Willcox DC, et al. 
Caloric restriction, the traditional 
Okinawan diet, and healthy aging: 
The diet of the world’s longest-lived 
people and its potential impact on 
morbidity and life span. Annals of 
the New York Academy of Sciences. 
2007;1114:434-455
[49] Peters R. Ageing and the brain. 
Postgraduate Medical Journal. 
2006;82(964):84-88
[50] Dal-Pan A, Pifferi F, et al. 
Cognitive performances are 
selectively enhanced during chronic 
caloric restriction or resveratrol 
supplementation in a primate. PLoS 
One. 2011;6(1):e16581
[51] Bondolfi L, Ermini F, et al. Impact 
of age and caloric restriction on 
neurogenesis in the dentate gyrus of 
C57BL/6 mice. Neurobiology of Aging. 
2004;25(3):333-340
[52] Patel NV, Gordon MN, et al. 
Caloric restriction attenuates Abeta-
deposition in Alzheimer transgenic 
models. Neurobiology of Aging. 
2005;26(7):995-1000
Feed Your Mind - How Does Nutrition Modulate Brain Function throughout Life?
18
[53] Pani G. Neuroprotective effects 
of dietary restriction: Evidence 
and mechanisms. Seminars in 
Cell & Developmental Biology. 
2015;40:106-114
[54] Nisoli E, Tonello C, et al. 
Calorie restriction promotes 
mitochondrial biogenesis by inducing 
the expression of eNOS. Science. 
2005;310(5746):314-317
[55] Lee IH, Cao L, et al. A role for the 
NAD-dependent deacetylase Sirt1 in the 
regulation of autophagy. Proceedings 
of the National Academy of Sciences 
of the United States of America. 
2008;105(9):3374-3379
[56] Martins R, Lithgow GJ, Link W.  
Long live FOXO: Unraveling the role of 
FOXO proteins in aging and longevity. 
Aging Cell. 2016;15(2):196-207
[57] Hardie DG, Ashford MLJ. AMPK: 
Regulating energy balance at the cellular 
and whole body levels. Physiology. 
2014;29(2):99-107
[58] Apfeld J, O’Connor G, et al. 
The AMP-activated protein kinase 
AAK-2 links energy levels and 
insulin-like signals to life span in 
C. Elegans. Genes & Development. 
2004;18(24):3004-3009
[59] Cantó C, Jiang L, et al. 
Interdependence of AMPK and SIRT1 
for metabolic adaptation to fasting 
and exercise in skeletal muscle. Cell 
Metabolism. 2010;11(3, 3):213-219
[60] Kenyon CJ. The genetics of ageing. 
Nature. 2010;464(7288):504-512
[61] Hulbert AJ, Pamplona R, et al. 
Life and death: Metabolic rate, 
membrane composition, and life span 
of animals. Physiological Reviews. 
2007;87(4):1175-1213
[62] Alers S, Löffler A, et al. Role of 
AMPK-mTOR-Ulk1/2 in the regulation 
of autophagy: Cross talk, shortcuts, 
and feedbacks. Molecular and Cellular 
Biology. 2012;32(1, 1):2-11
[63] Kamada Y, Sekito T, et al. 
Autophagy in yeast: A TOR-mediated 
response to nutrient starvation. 
Current Topics in Microbiology and 
Immunology. 2004;279:73-84
[64] Soare A, Cangemi R, et al. 
Long-term calorie restriction, but 
not endurance exercise, lowers core 
body temperature in humans. Aging. 
2011;3(4):374-379
[65] Hunt N, Li G, et al. Effect of 
calorie restriction and refeeding 
on skin wound healing in the rat. 
Age (Dordrecht, Netherlands). 
2012;34(6):1453-1458
[66] Nikolai S, Pallauf K, et al. Energy 
restriction and potential energy 
restriction mimetics. Nutrition Research 
Reviews. 2015;28(2):100-120
[67] Bensalem J, Dudonné S, et al. 
Polyphenols from grape and blueberry 
improve episodic memory in healthy 
elderly with lower level of memory 
performance: A bicentric double-blind, 
randomized, placebo-controlled clinical 
study. The Journals of Gerontology. 
Series A, Biological Sciences and 
Medical Sciences. 2018
[68] Bensalem J, Dudonné S, et al. 
Polyphenol-rich extract from grape and 
blueberry attenuates cognitive decline 
and improves neuronal function in aged 
mice. Journal of Nutritional Science. 
2018;7:e19
[69] Howitz K, Bitterman K, et al. Small 
molecule activators of sirtuins extend 
Saccharomyces cerevisiae life span. 
Nature. 2003;425(6954):191-196
[70] Baur J, Pearson K, et al. Resveratrol 
improves health and survival of 
mice on a high-calorie diet. Nature. 
2006;444(7117):337-342
19
Dietary Impact on Neuronal Autophagy Control and Brain Health
DOI: http://dx.doi.org/10.5772/intechopen.85228
[71] Mattison J, Wang M, et al. 
Resveratrol prevents high fat/
sucrose diet-induced central arterial 
wall inflammation and stiffening in 
nonhuman primates. Cell Metabolism. 
2014;20(1, 1):183-190
[72] Jimenez-Gomez Y, Mattison J, et al. 
Resveratrol improves adipose insulin 
signaling and reduces the inflammatory 
response in adipose tissue of rhesus 
monkeys on high-fat, high-sugar diet. 
Cell Metabolism. 2013;18(4):533-545
[73] Gambini J, Inglés M, et al. 
Properties of resveratrol: In vitro and 
In vivo studies about metabolism, 
bioavailability, and biological effects in 
animal models and humans. Oxidative 
Medicine and Cellular Longevity. 
2015;2015:837042
[74] Timmers S, Konings E, et al. Calorie 
restriction-like effects of 30 days of 
resveratrol supplementation on energy 
metabolism and metabolic profile 
in obese humans. Cell Metabolism. 
2011;14(5):612-622
[75] Poulsen M, Vestergaard P, et al. 
High-dose resveratrol supplementation 
in obese men: An investigator-initiated, 
randomized, placebo-controlled clinical 
trial of substrate metabolism, insulin 
sensitivity, and body composition. 
Diabetes. 2013;62(4):1186-1195
[76] Mukherjee S, Ray D, et al. Effects of 
Longevinex on cardioprotection and its 
mechanisms of action. Canadian Journal 
of Physiology and Pharmacology. 
2010;88(11):1017-1025
[77] Vingtdeux V, Giliberto L, et al. 
AMP-activated protein kinase signaling 
activation by resveratrol modulates 
amyloid-beta peptide metabolism. 
The Journal of Biological Chemistry. 
2010;285(12):9100-9113
[78] Turner RS, Thomas R, et al. A 
randomized, double-blind, placebo-
controlled trial of resveratrol for 
Alzheimer disease. Neurology. 
2015;85(16):1383-1391
[79] Porquet D, Griñán-Ferré C, 
et al. Neuroprotective role of trans-
resveratrol in a murine model of 
familial Alzheimer’s disease. The 
Journal of Alzheimer's Disease. 
2014;42(4):1209-1220
[80] Passtoors W, Beekman M, et al. 
Gene expression analysis of mTOR 
pathway: Association with human 
longevity. Aging Cell. 2013;12(1):24-31
[81] Anisimov V, Zabezhinski M,  
et al. Rapamycin increases life 
span and inhibits spontaneous 
tumorigenesis in inbred female 
mice. Cell Cycle (Georgetown, Tex.). 
2011;10(24):4230-4236
[82] Cunningham J, Rodgers J, et al. 
mTOR controls mitochondrial oxidative 
function through a YY1-PGC-1alpha 
transcriptional complex. Nature. 
2007;450(7170):736-740
[83] Majumder S, Caccamo A, et al. 
Lifelong rapamycin administration 
ameliorates age-dependent cognitive 
deficits by reducing IL-1β and 
enhancing NMDA signaling. Aging Cell. 
2012;11(2):326-335
[84] Woo H, Chung H, et al. 
Preclinical evaluation of injectable 
sirolimus formulated with polymeric 
nanoparticle for cancer therapy. 
International Journal of Nanomedicine. 
2012;7:2197-2208
[85] Samidurai A, Salloum F, et al. 
Chronic treatment with novel 
nanoformulated micelles of rapamycin, 
Rapatar, protects diabetic heart 
against ischaemia/reperfusion injury. 
British Journal of Pharmacology. 
2017;174(24):4771-4784
[86] Comas M, Toshkov I, et al. New 
nanoformulation of rapamycin Rapatar 
extends life span in homozygous 
Feed Your Mind - How Does Nutrition Modulate Brain Function throughout Life?
20
p53−/− mice by delaying carcinogenesis. 
Aging. 2012;4(10):715-722
[87] Viollet B, Guigas B, et al. Cellular 
and molecular mechanisms of 
metformin: An overview. Clinical 
Science (London, England: 1979). 
2012;122(6):253-270
[88] Nelson L, Valentine R, et al. A 
novel inverse relationship between 
metformin-triggered AMPK-SIRT1 
signaling and p53 protein abundance 
in high glucose-exposed HepG2 cells. 
American Journal of Physiology. Cell 
Physiology. 2012;303(1, 1):C4-C13
[89] Foretz M, Guigas B, et al. 
Metformin: From mechanisms of 
action to therapies. Cell Metabolism. 
2014;20(6):953-966
[90] Sridhar G, Lakshmi G, et al. 
Emerging links between type 2 diabetes 
and Alzheimer’s disease. World Journal 
of Diabetes. 2015;6(5):744-751
[91] Hsu C-C, Wahlqvist M, et al. 
Incidence of dementia is increased in 
type 2 diabetes and reduced by the 
use of sulfonylureas and metformin. 
The Journal of Alzheimer's Disease. 
2011;24(3):485-493
[92] Imfeld P, Bodmer M, et al. 
Metformin, other antidiabetic drugs, 
and risk of Alzheimer’s disease: A 
population-based case-control study. 
Journal of the American Geriatrics 
Society. 2012;60(5):916-921
[93] Lane M, Ingram D, Roth GS. 
2-Deoxy-D-glucose feeding in rats 
mimics physiologic effects of calorie 
restriction. Journal of Anti-Aging 
Medicine. 1998;1(4):327-337
[94] Lee J, Bruce-Keller A, et al. 2-Deoxy-
D-glucose protects hippocampal neurons 
against excitotoxic and oxidative injury: 
Evidence for the involvement of stress 
proteins. Journal of Neuroscience 
Research. 1999;57(1, 1):48-61
[95] Duan W, Mattson M. Dietary 
restriction and 2-deoxyglucose 
administration improve behavioral 
outcome and reduce degeneration 
of dopaminergic neurons in 
models of Parkinson’s disease. 
Journal of Neuroscience Research. 
1999;57(2):195-206
[96] Yao J, Chen S, et al. 2-Deoxy-D-
glucose treatment induces ketogenesis, 
sustains mitochondrial function, and 
reduces pathology in female mouse 
model of Alzheimer’s disease. PLoS 
One. 2011;6(7):e21788
[97] Minor R, Smith D, et al. Chronic 
ingestion of 2-deoxy-D-glucose 
induces cardiac vacuolization and 
increases mortality in rats. Toxicology 
and Applied Pharmacology. 
2010;243(3):332-339
[98] Martinez-Lopez N, Athonvarangkul 
D, et al. Autophagy and aging. Advances 
in Experimental Medicine and Biology. 
2015;847:73-87
[99] He L, Lu J, Yue Z. Autophagy 
in ageing and ageing-associated 
diseases. Acta Pharmacologica Sinica. 
2013;34(5):605-611
[100] Eisenberg T, Abdellatif M, 
et al. Cardioprotection and life span 
extension by the natural polyamine 
spermidine. Nature Medicine. 
2016;22(12):1428-1438
[101] Schwarz C, Stekovic S, et al. 
Safety and tolerability of spermidine 
supplementation in mice and older 
adults with subjective cognitive decline. 
Aging. 2018;10(1):19-33
[102] Eisenberg T, Knauer H, et al. 
Induction of autophagy by spermidine 
promotes longevity. Nature Cell Biology. 
2009;11(11):1305-1314
[103] Soda K, Dobashi Y, et al. 
Polyamine-rich food decreases age-
associated pathology and mortality in 
21
Dietary Impact on Neuronal Autophagy Control and Brain Health
DOI: http://dx.doi.org/10.5772/intechopen.85228
aged mice. Experimental Gerontology. 
2009;44(11):727-732
[104] Soda K, Kano Y, et al. Increased 
polyamine intake inhibits age-associated 
alteration in global DNA methylation 
and 1,2-dimethylhydrazine-
induced tumorigenesis. PLoS One. 
2013;8(5):e64357
[105] Eisenberg T, Schroeder S, 
et al. A histone point mutation that 
switches on autophagy. Autophagy. 
2014;10(6):1143-1145
[106] du Toit A, Hofmeyr J-HS,  
Gniadek TJ, Loos B. Measuring 
autophagosome flux. Autophagy. 
2018;14(6):1060-1071
[107] Wirth M, Benson G, et al. The 
effect of spermidine on memory 
performance in older adults at risk for 
dementia: A randomized controlled 
trial. Cortex: A Journal Devoted to 
the Study of the Nervous System and 
Behavior. 2018;109:181-188
[108] Kaizuka T, Morishita H, et al. An 
Autophagic flux probe that releases 
an internal control. Molecular Cell. 
2016;64(4):835-849
[109] Zhou H, Shang C, et al. Ciclopirox 
Olamine inhibits mTORC1 signaling 
by activation of AMPK. Biochemical 
Pharmacology. 2016;116:39-50
[110] Hayes C, Dey D, et al. Chronic 
Cladribine administration increases 
amyloid Beta peptide generation and 
plaque burden in mice. PLoS One. 
2012;7(10)
[111] Rainey M, Korostyshevsky D, 
et al. The antidepressant sertraline 
targets intracellular Vesiculogenic 
membranes in yeast. Genetics. 
2010;185(4):1221-1233
[112] Williams A, Sarkar S, et al. Novel 
targets for Huntington’s disease in 
an mTOR-independent autophagy 
pathway. Nature Chemical Biology. 
2008;4(5):295-305
[113] Abdulhaq H, Rossetti J. The role 
of azacitidine in the treatment of 
myelodysplastic syndromes. Expert 
Opinion on Investigational Drugs. 
2007;16(12):1967-1975
[114] Cătană C-S, Atanasov A, et al. 
Natural products with anti-aging 
potential: Affected targets and 
molecular mechanisms. Biotechnology 
Advances. 2018;36(6):1649-1656
[115] Popkin B, Adair LS, et al. Global 
nutrition transition and the pandemic 
of obesity in developing countries. 
Nutrition Reviews. 2012;70(1):3-21
[116] Mattison J, Vaughan K. An 
overview of nonhuman primates 
in aging research. Experimental 
Gerontology. 2017;94:41-45
